Biswas, Piyashi
Dodakian, Lucy
Wang, Po T.
Johnson, Christopher A.
See, Jill
Chan, Vicky
Chou, Cathy
Lazouras, Wendy
McKenzie, Alison L.
Reinkensmeyer, David J.
Nguyen, Danh V.
Cramer, Steven C.
Do, An H.
Nenadic, Zoran
Funding for this research was provided by:
National Institutes of Health, United States (5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457, 5R01HD095457)
Article History
Received: 25 May 2024
Accepted: 4 June 2024
First Online: 13 June 2024
Declarations
:
: The study protocol and related procedures are approved by the UCI IRB; study protocol #20194936; initial approval on January 08, 2021, and last amended approval on December 21, 2023. All participants provide written informed consent.
: Not Applicable.
: S.C.C. serves as a consultant for Constant Therapeutics, BrainQ, Myomo, MicroTransponder, Panaxium, Elevian, Stream Biomedical, NeuroTrauma Sciences, and TRCare.